Each patient can have a different experience with bispecific antibody therapy and how it affects their quality of life. Studies are still emerging on the long-term quality of life effects of these treatments.

Some early findings are detailed below:

Patients on teclistamab have improved their quality of life in pain management with no overall change in physical function and fatigue.
Treatment with GPRC5D-targeting bispecifics such as talquetamab can significantly impact the quality of life due to early-onset side effects like severe loss of taste or taste changes. However, patients also reported an improvement in pain, fatigue, and physical functioning.
Elranatamab patients are reported to maintain or improve their quality of life in areas such as pain, disease symptoms, side effects of treatment, body image, and future perspectives of treatment.

As more patients qualify for bispecific antibody therapy and more time passes, real-world data will provide concrete evidence of the impact of bispecific antibody therapies on quality of life.